Effect of the P-glycoprotein inhibitor, R(+)-verapamil on the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica

Veterinary Parasitology

Volumn 195, Issue 1-2, 2013, Pages 72-86

  Savage, J ^a   Meaney, M ^a   Brennan, G P ^a   Hoey, E ^a   Trudgett, A ^a   Fairweather, I ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Fasciola hepatica; Liver fluke; P glycoprotein inhibition; R(+) verapamil; Scanning electron microscopy; Triclabendazole resistance

Indexed keywords

GLYCOPROTEIN P INHIBITOR; TRICLABENDAZOLE; VERAPAMIL; BENZIMIDAZOLE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; SULFOXIDE; TRICLABENDAZOLE SULFOXIDE;

ANIMAL TISSUE; ANTITREMATODAL DRUG RESISTANCE; ANTITREMATODAL DRUG SENSITIVITY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TRANSPORT; FASCIOLA HEPATICA; INCUBATION TIME; MALE; MICROBIAL MORPHOLOGY; NONHUMAN; RAT; SCANNING ELECTRON MICROSCOPY; ANIMAL; ANTAGONISTS AND INHIBITORS; CYTOLOGY; DRUG EFFECTS; FASCIOLIASIS; PARASITOLOGY; SPRAGUE DAWLEY RAT;

FASCIOLA HEPATICA;

ANIMALS; BENZIMIDAZOLES; DRUG RESISTANCE; FASCIOLA HEPATICA; FASCIOLIASIS; MALE; MICROSCOPY, ELECTRON, SCANNING; P-GLYCOPROTEINS; RATS; RATS, SPRAGUE-DAWLEY; SULFOXIDES; VERAPAMIL;

EID: 84878463047     PISSN: 03044017     EISSN: 18732550     Source Type: Journal    
DOI: 10.1016/j.vetpar.2013.03.007     Document Type: Article

References (74)

1. Alvarez A.I., Merino G., Molina A.J., Pulido M.M., McKellar Q.A., Prieto J.G. Role of ABC transporters in veterinary drug research and parasite resistance. Curr. Drug Deliv. 2006, 3:199-206.
2. Alvarez L.I., Solana H.D., Mottier M.L., Virkel G.L., Fairweather I., Lanusse C.E. Altered drug influx/efflux and enhanced metabolic activity in triclabendazole resistant liver flukes. Parasitology 2005, 131:501-510.
3. Alvinerie M., Dupuy J., Kiki-Mvouaka S., Sutra J.-F., Lespine A. Ketoconazole increases the plasma levels of ivermectin in sheep. Vet. Parasitol. 2008, 157:117-122.
4. Ardelli B.F., Prichard R.K. Effects of ivermectin and moxidectin on the transcription of genes coding for multidrug resistance associated proteins and behaviour in Caenorhabditis elegans. J. Nematol. 2008, 40:290-298.
5. Ardelli B.F., Prichard R.K. Inhibition of P-glycoprotein enhances sensitivity of Caenorhabditis elegans to ivermectin. Vet. Parasitol. 2013, 191:264-275.
6. Bartley D.J., Mc Allister H., Bartley Y., Dupuy J., Menez C., Alvinerie M., Jackson F., Lespine A. P-glycoprotein interfering agents potentiate ivermectin susceptibility in ivermectin sensitive and resistant isolates of Teladorsagia circumcinta and Haemonchus contortus. Parasitology 2009, 136:1081-1088.
7. Bartley D.J., Morrison A.A., Dupuy J., Bartley Y., Sutra J.F., Menez C., Alvineire M., Jackson F., Devin L., Lespine A. Influence of Pluronic 85 and ketoconazole on disposition and efficacy of ivermectin in sheep infected with a multiple resistant Haemonchus contortus isolate. Vet. Parasitol. 2012, 187:464-472.
8. Benchaoui H.A., McKellar Q.A. Interaction between fenbendazole and piperonyl butoxide: pharmacokinetic and pharmacodynamic implications. J. Pharm. Pharmacol. 1996, 48:753-759.
9. Coles G.C., Stafford K.A. Activity of oxyclozanide, nitroxynil, clorsulon and albendazole against triclabendazole-resistant Fasciola hepatica. Vet. Rec. 2001, 148:723-724.
10. Coles G.C., Rhodes A.C., Stafford K.A. Activity of closantel against adult triclabendazole-resistant Fasciola hepatica. Vet. Rec. 2000, 146:504.
11. Devine C., Brennan G.P., Lanusse C.E., Alvarez L.I., Trudgett A., Hoey E., Fairweather I. Effect of the metabolic inhibitor, methimazole on the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica. Parasitology 2009, 136:183-192.
12. Devine C., Brennan G.P., Lanusse C.E., Alvarez L.I., Trudgett A., Hoey E., Fairweather I. Inhibition of cytochrome P450-mediated metabolism enhances ex vivo susceptibility of Fasciola hepatica to triclabendazole. Parasitology 2010, 137:871-880.
13. Devine C., Brennan G.P., Lanusse C.E., Alvarez L.I., Trudgett A., Hoey E., Fairweather I. Potentiation of triclabendazole sulphoxide-induced tegumental disruption by methimazole in a triclabendazole-resistant isolate of Fasciola hepatica. Parasitol. Res. 2010, 106:1351-1363.
14. Devine C., Brennan G.P., Lanusse C.E., Alvarez L.I., Trudgett A., Hoey E., Fairweather I. Enhancement of the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica using the metabolic inhibitor ketoconazole. Parasitol. Res. 2010, 107:337-353.
15. Devine C., Brennan G.P., Lanusse C.E., Alvarez L.I., Trudgett A., Hoey E.M., Fairweather I. Piperonyl butoxide enhances triclabendazole action against triclabendazole-resistant Fasciola hepatica. Parasitology 2011, 138:224-236.
16. Devine C., Brennan G.P., Lanusse C.E., Alvarez L.I., Trudgett A., Hoey E.M., Fairweather I. Enhancement of triclabendazole action in vivo against a triclabendazole-resistant isolate of Fasciola hepatica by co-treatment with ketoconazole. Vet. Parasitol. 2011, 177:305-315.
17. Devine C., Brennan G.P., Lanusse C.E., Alvarez L.I., Trudgett A., Hoey E., Fairweather I. Inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica. Parasitol. Res. 2011, 109:981-995.
18. Devine C., Brennan G.P., Lanusse C.E., Alvarez L.I., Trudgett A., Hoey E., Fairweather I. Erratum to: Inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica. Parasitol. Res. 2011, 109:1209-1223.
19. Devine C., Brennan G.P., Lanusse C.E., Alvarez L.I., Trudgett A., Hoey E., Fairweather I. Potentiation of triclabendazole action in vivo against a triclabendazole-resistant isolate of Fasciola hepatica following its co-administration with the metabolic inhibitor, ketoconazole. Vet. Parasitol. 2012, 184:37-47.
20. Dupuy J., Larrieu G., Sutra J.F., Lespine A., Alvinerie M. Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: quercetin. Vet. Parasitol. 2003, 112:337-347.
21. Echizen H., Brecht T., Niedergesass S., Vogelgesang B., Eichelbaum M. The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans. Am. Heart J. 1985, 109:210-217.
22. Fairweather I. Triclabendazole: new skills to unravel an old(ish) enigma. J. Helminthol. 2005, 79:227-234.
23. Fairweather I. Triclabendazole progress report, 2005-2009: an advancement of learning?. J. Helminthol. 2009, 83:139-150.
24. Fairweather I. Liver fluke isolates: a question of provenance. Vet. Parasitol. 2011, 176:1-8.
25. Fairweather I. Reducing the future threat from (liver) fluke: realistic prospect or quixotic fantasy?. Vet. Parasitol. 2011, 180:133-143.
26. Fairweather I., Threadgold L.T., Hanna R.E.B. Development of Fasciola hepatica in the mammalian host. Fasciolosis 1999, 47-111. CAB International, Wallingford, Oxon, UK. J.P. Dalton (Ed.).
27. Fairweather I., McShane D.D., Shaw L., Ellison S.E., O'Hagan N.T., York E.A., Trudgett A., Brennan G.P. Development of an egg hatch assay for the diagnosis of triclabendazole resistance in Fasciola hepatica: proof of concept. Vet. Parasitol. 2012, 183:249-259.
28. Flanagan A.M., Edgar H.W.J., Forster F., Gordon A.W., Hanna R.E.B., McCoy M., Brennan G.P., Fairweather I. Standardisation of a coproantigen reduction test (CRT) protocol for the diagnosis of resistance to triclabendazole in Fasciola hepatica. Vet. Parasitol. 2011, 176:34-42.
29. Halferty L., Brennan G.P., Hanna R.E.B., Edgar H.W., Meaney M., McConville M., Trudgett A., Hoey L., Fairweather I. Tegumental surface changes in juvenile Fasciola hepatica in response to treatment in vivo with triclabendazole. Vet. Parasitol. 2008, 155:49-58.
30. Halferty L., Brennan G.P., Trudgett A., Hoey L., Fairweather I. Relative activity of triclabendazole metabolites against the liver fluke, Fasciola hepatica. Vet. Parasitol. 2009, 159:126-138.
31. Hanna R.E.B., Edgar H.W.J., McConnell S., Toner E., McConville M., Brennan G.P., Devine C., Flanagan A., Halferty L., Meaney M., Shaw L., Moffett D., McCoy M., Fairweather I. Fasciola hepatica: histological changes in the reproductive structures of triclabendazole (TCBZ)-sensitive and TCBZ-resistant flukes collected from experimentally-infected sheep one to four days after treatment with TCBZ and the related benzimidazole derivative, compound alpha. Vet. Parasitol. 2010, 168:240-254.
32. Hennessy D.R., Lacey E., Steel J.W., Prichard R.K. The kinetics of triclabendazole disposition in sheep. J. Vet. Pharmacol. Ther. 1987, 10:64-72.
33. Holmes, S.D., 1983. In vitro studies into the mode of action of anthelmintics on the liver fluke, Fasciola hepatica L. Ph.D. Thesis. The Queen's University of Belfast, Northern Ireland.
34. James C.E., Davey M.W. Increased expression of ABC transport proteins is associated with ivermectin resistance in the model nematode Caenorhabditis elegans. Int. J. Parasitol. 2009, 39:213-220.
35. Kageyama M., Namiki H., Fukushima H., Ito Y., Shibata N., Takada K. In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. Biol. Pharm. Bull. 2005, 28:316-322.
36. Kasinathan R.S., Morgan W.M., Greenberg R.M. Schistosoma mansoni express higher levels of multidrug resistance-associated protein 1 (SmMRP1) in juvenile worms and in response to praziquantel. Mol. Biochem. Parasitol. 2010, 173:25-31.
37. Kasinathan R.S., Greenberg R.M. Pharmacology and potential physiological significance of schistosome multidrug resistance transporters. Exp. Parasitol. 2012, 132:2-6.
38. Kerboeuf D., Riou M. Efflux pump inhibitors: a progress in parasitic nematode control. Bull. Acad. Vét. France 2011, 164:257-264.
39. Kim R.B., Wandel C., Leake B., Cvetkovic M., Fromm M.F., Dempsye P.J., Roden M.M., Belas F., Chaudhary A.K., Roden D.M., Wood A.J., Wilkinson G.R. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. 1999, 16:408-414.
40. Lespine A., Alvinerie M., Vercruysse J., Prichard R.K., Geldhof P. ABC transporter modulation: a strategy to enhance the activity of macrocyclic lactone anthelmintics. Trends Parasitol. 2008, 24:293-298.
41. Lespine A., Ménez C., Bourguinat C., Prichard R.K. P-glycoproteins and other multidrug resistance transporters in the pharmacology of anthelmintics: prospects for reversing transport-dependent anthelmintic resistance. Int. J. Parasitol.: Drugs Drug Resist. 2012, 2:58-75.
42. Lifschitz A., Entrocasso C., Alvarez L., Lloberas M., Ballent M., Manazza G., Virkel G., Borda B., Lanusse C. Interference with P-glycoprotein improves ivermectin activity against adult resistant nematodes in sheep. Vet. Parasitol. 2010, 172:291-298.
43. Lifschitz A., Suarez V.H., Sallovitz J., Cristel S.L., Imperiale F., Ahoussou S., Schiavi C., Lanusse C. Cattle nematodes resistant to macrocyclic lactones: comparative effects of P-glycoprotein modulation on the efficacy and disposition kinetics of ivermectin and moxidectin. Exp. Parasitol. 2010, 125:172-178.
44. López-García M.L., Torrado S., Torrado S., Martínez A.R., Bolás F. Methimazole-mediated enhancement of albendazole oral bioavailability and anthelmintic effects against parenteral stages of Trichinella spiralis in mice: the influence of the dose regime. Vet. Parasitol. 1998, 75:209-219.
45. McConville M., Brennan G.P., McCoy M., Castillo R., Hernández-Campos A., Ibarra F., Fairweather I. Adult triclabendazole-resistant Fasciola hepatica: surface and subsurface tegumental responses to in vitro treatment with the sulphoxide metabolite of the experimental fasciolicide compound alpha. Parasitology 2006, 133:195-208.
46. McConville M., Brennan G.P., Flanagan A., Edgar H.W.J., Hanna R.E.B., McCoy M., Gordon A.W., Castillo R., Hernández-Campos A., Fairweather I. An evaluation of the efficacy of compound alpha and triclabendazole against two isolates of Fasciola hepatica. Vet. Parasitol. 2009, 162:75-88.
47. McConville M., Brennan G.P., Flanagan A., Hanna R.E.B., Edgar H.W.J., Castillo R., Hernández-Campos A., Fairweather I. Surface changes in adult Fasciola hepatica following treatment in vivo with the experimental fasciolicide, compound alpha. Parasitol. Res. 2009, 105:757-767.
48. McCoy M.A., Fairweather I., Brennan G.P., Kenny J.M., Ellison S., Forbes A.B. The efficacy of nitroxynil and triclabendazole administered synchronously against juvenile triclabendazole-resistant Fasciola hepatica in sheep. Res. Vet. Sci. 2005, 78(Suppl. A):33.
49. Meaney M., Allister J., McKinstry B., McLaughlin K., Brennan G.P., Forbes A.B., Fairweather I. Fasciola hepatica: morphological effects of a combination of triclabendazole and clorsulon against mature fluke. Parasitol. Res. 2006, 99:609-621.
50. Meaney, M., Savage, J., Brennan, G.P., Hoey, E., Trudgett, A., Fairweather, I. Increased susceptibility of a triclabendazole (TCBZ)-resistant isolate of Fasciola hepatica to TCBZ following co-incubation in vitro with the P-glycoprotein inhibitor, R(+)-verapamil. Parasitology (in press).
51. Messerli S.M., Kasinathan R.S., Morgan W., Spranger S., Greenberg R.M. Schistosoma mansoni P-glycoprotein levels increase in response to praziquantel exposure and correlate with reduced praziquantel susceptibility. Mol. Biochem. Parasitol. 2009, 167:54-59.
52. Molento M.B., Prichard R.K. Effects of the multidrug-reversing agents verapamil and CL 347,099 on the efficacy of ivermectin or moxidectin against unselected and drug-selected strains of Haemonchus contortus in jirds. Parasitol. Res. 1999, 85:1007-1011.
53. Mottier L., Alvarez L., Ceballos L., Lanusse C. Drug transport in helminth parasites: passive diffusion of benzimidazole anthelmintics. Exp. Parasitol. 2006, 113:49-57.
54. Mottier L., Alvarez L., Fairweather I., Lanusse C. Resistance-induced changes in triclabendazole transport in Fasciola hepatica: ivermectin reversal effect. J. Parasitol. 2006, 6:1355-1360.
55. Pelkonen O., Turpeinen M., Hakkola M., Honkakoski P., Hukkanen J., Raunio H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch. Toxicol. 2008, 82:667-715.
56. Prichard R.K., Roulet A. ABC transporters and β-tubulin in macrocyclic lactone resistance: prospects for marker development. Parasitology 2007, 134:1123-1132.
57. Robinson M.W., Lawson J., Trudgett A., Hoey E.M., Fairweather I. The comparative metabolism of triclabendazole sulphoxide by triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica. Parasitol. Res. 2004, 92:205-210.
58. Robinson M.W., Trudgett A., Hoey E.M., Fairweather I. Triclabendazole-resistant Fasciola hepatica: β-tubulin and response to in vitro treatment with triclabendazole. Parasitology 2002, 124:325-338.
59. Ryan L., Hoey E., Trudgett A., Fairweather I., Fuchs M., Robinson M.W., Chambers E., Timson D.J., Ryan E., Feltwell T., Ivens A., Bentley G., Johnston D. Fasciola hepatica expresses multiple α- and β-tubulin isotypes. Mol. Biochem. Parasitol. 2008, 159:73-78.
60. Sánchez-Bruni S.F.S., Fusé L.A., Moreno L., Saumell C.A., Álvarez L.I., Fiel C., McKellar Q.A., Lanusse C.E. Changes to oxfendazole chiral kinetics and anthelmintic efficacy induced by piperonyl butoxide in horses. Equine Vet. J. 2005, 37:257-262.
61. Savage, J., 2010. Studies on the mechanism of resistance to triclabendazole in the liver fluke, Fasciola hepatica. Ph.D. Thesis. The Queen's University of Belfast, Northern Ireland.
62. Stitt L.E., Tompkins J.B., Dooley L.A., Ardelli B.F. ABC transporters influence sensitivity of Brugia malayi to moxidectin and have potential roles in drug resistance. Exp. Parasitol. 2011, 129:137-144.
63. Tompkins J.B., Stitt L.E., Morrissette A.M., Ardelli B.F. The role of Brugia malayi ATP-binding cassette (ABC) transporters in potentiating drug sensitivity. Parasitol. Res. 2011, 109:1311-1322.
64. Toner E., McConvery F., Brennan G.P., Meaney M., Fairweather I. A scanning electron microscope study on the route of entry of triclabendazole into the liver fluke, Fasciola hepatica. Parasitology 2009, 136:523-535.
65. Toner E., Brennan G.P., McConvery F., Meaney M., Fairweather I. A transmission electron microscope study on the route of entry of triclabendazole into the liver fluke, Fasciola hepatica. Parasitology 2010, 137:855-870.
66. Toner E., Brennan G.P., Hanna R.E.B., Edgar H.W.J., Fairweather I. Tegumental surface changes in adult Fasciola hepatica in response to treatment in vivo with triclabendazole in the sheep host. Vet. Parasitol. 2010, 172:238-248.
67. Varma M.V.S., Ashkraj Y., Dey C.S., Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol. Res. 2003, 48:347-359.
68. Wang E.-J., Lew K., Casciano N., Clement R.P., Johnson W.W. Interaction of common azole antifungals with P glycoprotein. Antimicrob. Agents Chemother. 2002, 46:160-165.
69. Ward K.W., Stelman G.J., Morgan J.A., Zeigler K.S., Azzarano L.M., Kehler J.R., McSurdy-Freed J.E., Proksch J.W., Smith B.R. Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics, II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey. Drug Metab. Dispos. 2004, 32:172-177.
70. Wilkinson R., Law C.J., Hoey E.M., Fairweather I., Brennan G.P., Trudgett A. An amino acid substitution in a Fasciola hepatica P-glycoprotein from triclabendazole-resistant and triclabendazole-susceptible populations. Mol. Biochem. Parasitol. 2012, 186:69-72.
71. Xu M., Molento M., Blackhall W., Riberio P., Beech R., Prichard R. Ivermectin resistance in nematodes may be caused by alteration of P-glycoprotein homolog. Mol. Biochem. Parasitol. 1998, 91:327-335.
72. Yan R., Urdaneta-Marquez L., Keller K., James C.E., Davey M.W., Prichard R.K. The role of several ABC transporter genes in ivermectin resistance in Caenorhabditis elegans. Vet. Parasitol. 2012, 190:519-529.
73. Ye Z.G., Van Dyke K. Reversal of chloroquine resistance in falciparum malaria independent of calcium channels. Biochem. Biophys. Res. Commun. 1988, 30:476-481.
74. Zhang Y., Hsieh Y., Izumi T., Lin E.T., Benet L.Z. Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. J. Pharmacol. Exp. Ther. 1998, 287:246-252.